Nurses are on the frontlines of increasing access to health care and as a nurse, my first priority is always the patient. There was a recent case that demonstrates the importance of the role of nursing in achieving needed services for patients. In this case, a young person was a victim of sexual assault resulting in HIV exposure. The MidAtlantic AETC had conducted training on post-exposure prophylaxis (PEP) and one of our participants in that training was responsible for making sure that the patient received nPEP.
What is a dental emergency?
I often get this question from non-dental personnel including case managers, physician assistants, nurses and nurse practitioners. The following is a quick list of questions you can ask patients to guide dental referrals for emergency care:
A recent study that was conducted among 1200 HIV patient of whom 600 each belonged to with ART and without ART and the occurrence of oral candidiasis and oral hairy leukoplakia. This study shows that oral candidiasis and leukoplakia was less among patients on ART as well as a decrease in the number of opportunistic infections. This is important as oral manifestations might serve as an important marker for monitoring restoration of immune function and ART failure.
The question I most commonly get asked by oral health providers is...
Do I pre-medicate patients based on a high viral load and low CD4 count?
In the United States, it is estimated that 1.1 million people are living with HIV.
The U.S. Department of Health and Human Services currently recommends that every person living with HIV begin antiretroviral therapy (ART) as soon as possible after diagnosis.
According to a new study published in the Journal Annals of Internal Medicine, one in nine American men is infected with the oral form of the human papillomavirus (HPV). Nationwide, rates of oral HPV infection are 11.5% of men vs. 3.2% women. HPV 16, the most common type of high-risk HPV and known to contribute to head and neck cancers, was six times higher in men than women.
I had the honor to help develop the first legal syringe access program (SAP) in Atlantic City, NJ, almost 10 years ago. In 2006, the New Jersey legislature passed the Blood-Borne Disease Harm Reduction Act, which allowed for the establishment of up to six pilot SAPs in NJ; however, approval from each selected city’s government was required before opening.
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the DOR arm was found to be noninferior to the DRV arm (see CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment).